Skip to content
Study details
Enrolling now

Lofexidine and Buprenorphine for PTSD and Opioid Relapse

Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
NCT IDNCT04360681ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

120

Study length

about 4.8 years

Ages

18–70

Locations

2 sites in TX

What this study is about

Researchers are testing if lofexidine, taken with buprenorphine, helps reduce symptoms of both opioid use disorder and post-traumatic stress disorder in veterans. The trial will compare the safety and effectiveness of buprenorphine alone versus buprenorphine plus lofexidine.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Lofexidine
  • 2.Take Placebo oral tablet

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralOral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

lofexidine

Drug routes

oral (Oral Tablet), oral

Endpoints

Primary: Opioid Use, PTSD Symptoms (Checklist)

Secondary: PTSD Symptoms

Body systems

Psychiatry / Mental Health